⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RGNX News
REGENXBIO Inc.
Form 8-K
sec.gov
RGNX
REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
prnewswire.com
RGNX
REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
prnewswire.com
RGNX
FORE Biotherapeutics to Participate in Upcoming Investor Conferences
businesswire.com
RGNX
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
prnewswire.com
RGNX
Catalyst Monitor: Q2 2026 Outlook Report - Trial Initiations, Completions, Top-line Results, Regulatory Filings, PDUFA Dates, and Expected Approvals
globenewswire.com
RPTX
ARVN
RGNX
Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations | DelveInsight
globenewswire.com
ADAG
ABBV
BIIB
BMRN
BLRX
CNSP
CYCN
GEN
GILD
GRAF
GSK
HSIC
HUBS
IBIO
INCY
JAZZ
JNJ
MAGN
MARA
MRK
NVS
OMER
PFE
PRGS
REGN
RGNX
SRPT
TENB
TGLS
TGTX
TNDM
TXG
VRTX
LifeSci Advisors Expands Team with Appointment of Tricia Truehart in Investor Relations
globenewswire.com
RGNX
Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain
prnewswire.com
RGNX
Lifshitz Law PLLC Announces Investigations of PayPal Holdings, Inc. (NASDAQ:PYPL), Enphase Energy, Inc. (NASDAQ:ENPH), REGENXBIO Inc. (NASDAQ:RGNX), and Kyndryl Holdings, Inc. (NYSE:KD)
accessnewswire.com
PYPL
ENPH
RGNX
KD